Plain-English translation of NCT07483983 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called in people with advanced lung cancer or pancreatic cancer who have a specific genetic change (KRAS G12D mutation). Researchers want to see if this medication works and to understand how it helps some patients while others may develop resistance to it over time.
Many people with these cancers run out of treatment options after standard therapies stop working. This medication targets a genetic mutation that is common in both lung and pancreatic cancer, offering a potential new pathway for patients who have already tried other treatments.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion once a week in 21-day treatment cycles. You would continue treatment until your cancer progresses, you experience unacceptable side effects, or you choose to stop. Throughout the trial, you would have regular clinic visits for blood tests, scans to measure your tumors, and biopsies (tissue samples) before starting treatment, during treatment, and at the end—particularly if your cancer starts growing again after initially improving.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
France